CliffBio
biologic

Benlysta

belimumab

Loss of exclusivityMarch 2023projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline →See this company's full patent-cliff portfolio

Drug detail

Brand nameBenlysta
Active ingredientbelimumab
Strength120MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2011
Marketing statusRx

More from GlaxoSmithKline

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Benlysta patent cliff — loss of exclusivity March 2023 | CliffBio